Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

2023-508594-84-00 Protocol PROICM 2021-02 GAB Therapeutic exploratory (Phase II) Ongoing, recruiting

Start 11 Jan 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 8 sites · Protocol PROICM 2021-02 GAB

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruiting
Participants planned 162
Countries 1
Sites 8

Metastatic pancreatic adenocarcinoma

Key facts

Sponsor
Institut Regional Du Cancer De Montpellier
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06], Not possible to specify, Diseases [C] - Neoplasms [C04]
Trial duration
11 Jan 2022 → ongoing
Decision date (initial)
2024-09-19
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-508594-84-00
EudraCT number
2021-001353-31
ClinicalTrials.gov
NCT05065801

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic pancreatic adenocarcinoma

VersionLevelCodeTermSystem organ class
21.1 LLT 10026314 Malignant neoplasm of pancreas metastatic 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Regional Du Cancer De Montpellier

Sponsor organisation
Institut Regional Du Cancer De Montpellier
Address
208 Avenue Des Apothicaires
City
Montpellier Cedex 5
Postcode
34298
Country
France

Scientific contact point

Organisation
Institut Regional Du Cancer De Montpellier
Contact name
Dr Fabienne Portalès

Public contact point

Organisation
Institut Regional Du Cancer De Montpellier
Contact name
catherine fiess

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 162 8
Rest of world 0

Investigational sites

France

8 sites · Ongoing, recruiting
Centre Catalan D'oncologie
Pyrénées-orientales, 80 Rue Pascal Marie Agasse, 66000, Perpignan
Institut Regional Du Cancer De Montpellier
Hérault, 208 Avenue Des Apothicaires, 34298, Montpellier Cedex 5
Centre Hospitalier Universitaire Grenoble Alpes
Isère, Boulevard De La Chantourne, Cs 10217, Grenoble Cedex 9
Centre Hospitalier Universitaire De Montpellier
Hérault, 80 Avenue Augustin Fliche, 34295, Montpellier Cedex 5
Centre Hospitalier De Perpignan
Pyrénées-orientales, 20 Avenue Du Languedoc, Cs 49954, Perpignan Cedex
Institut Godinot
Marne, 1 Rue Du General Koenig, 51100, Reims
Centre Hospitalier Universitaire De Saint Etienne
Loire, St Priest En Jarez, 25 Boulevard Pasteur, St Etienne Cedex 2
Centr Georges Francois Leclerc
Côte d'or, 1 Rue Professeur Marion, 21000, Dijon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2022-01-11 2022-01-11

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-19 France No conclusion
2024-09-09
2024-09-19
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-23 France Acceptable
2025-12-03
2025-12-08